This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Jeanette Leusen, PhD
Associate Professor, Head Immunotherapy Group at University Medical Center Utrecht


Jeanette Leusen received her PhD in 1995 at the University of Amsterdam (UvA), The Netherlands, and is now PI of the Immunotherapy research group (15 FTE) of the Center for Translational Immunology of the University Medical Center Utrecht. In the last 20 years Dr Leusen investigated FcR biology and the potential of IgA as a therapeutic antibody. She has co-authored about 110 peer-reviewed papers and is lead inventor on 5 patents concerning IgA. Since 2012 she is also head of the UMAB facility for antibody generation, and in 2018 she founded the spin-off company TigaTx, that is dedicated to proceed with engineered IgA towards the clinic.

Agenda Sessions

  • Keynote Introduction by Session Chair and KEYNOTE PRESENTATION with Live Q&A and Audience Interaction - Engineered IgA as Cancer Therapeutic

  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #7: CELL ENGAGERS FOR THE INNATE IMMUNE SYSTEM - To prepare for this discussion/Q&A, attendees should view the presentations from Session #7 in the Watch On-Demand Sessions Tab prior to this session

  • SESSION CHAIR: Mark Your Calendar for Thursday, August 27, 11:15-12:00 for the Live Speaker Q&A/Panel Discussion with the Speakers in this Session - Check the "Watch Live" Session Tab for Details. We Recommend That You Watch These On-Demand Presentations Prior to the Live Q&A/Panel

    On Demand